{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Alacizumab_Pegol",
  "nciThesaurus": {
    "casRegistry": "934216-54-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A pegylated, cross-linked, humanized divalent-Fab' antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab' antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs.",
    "fdaUniiCode": "ZL9780F883",
    "identifier": "C61438",
    "preferredName": "Alacizumab Pegol",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C1971"
    ],
    "synonyms": [
      "ALACIZUMAB PEGOL",
      "Alacizumab Pegol",
      "CDP-791"
    ]
  }
}